PRO51 COST-EFFECTIVENESS AND BUDGET IMPACT OF ONASEMNOGENE ABEPARVOVEC FOR SPINAL MUSCULAR ATROPHY TYPE 1: POST-HOC ANALYSIS OF A MODEL DEVELOPED BY ICER
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2381
https://www.valueinhealthjournal.com/article/S1098-3015(19)34759-X/fulltext
Title :
PRO51 COST-EFFECTIVENESS AND BUDGET IMPACT OF ONASEMNOGENE ABEPARVOVEC FOR SPINAL MUSCULAR ATROPHY TYPE 1: POST-HOC ANALYSIS OF A MODEL DEVELOPED BY ICER
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34759-X&doi=10.1016/j.jval.2019.09.2381
First page :
Section Title :
Open access? :
No
Section Order :
12081